Protagonist Therapeutics (PTGX) witnessed a pre-market surge of 6.41% on Monday, following the announcement of positive topline results from the Phase 3 VERIFY study of their investigational drug rusfertide in patients with polycythemia vera (PV).
The study met its primary endpoint, with a significantly higher proportion of patients achieving clinical response on rusfertide compared to placebo when added to standard of care treatment. Rusfertide, a first-in-class hepcidin mimetic peptide, also demonstrated success across all four key secondary endpoints, including the pre-specified primary endpoint for European Union regulators and patient-reported outcomes.
Importantly, rusfertide was generally well-tolerated, with no new safety findings observed in the study. Following these positive results, Protagonist will receive a $25 million milestone payment from their collaboration partner Takeda, as they plan to work together to submit the findings to regulatory agencies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.